FcRn Antibodies and Methods of Use Thereof
AssigneeMomenta Pharmaceuticals, Inc.
InventorsLeona E. Ling, Darrell Nix, Nicholas A. Cilfone
Life of this patent
Estimating the term…
Abstract
The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.
Claims24
-110. (canceled)
A method for treating or reducing the risk of developing a fetal and neonatal alloimmune and/or autoimmune disorder comprising administering to a pregnant women a composition comprising an antibody comprising a light chain having the amino acid sequence of SEQ ID NO:19 and a heavy chain having the amino acid sequence of SEQ ID NO:24.
(canceled)
-129. (canceled)
-158. (canceled)
Dependencies are inferred from the claim text.